Company / Cash & Equivalents
CV Sciences, Inc. Cash & Equivalents History
FY2018-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$611.0K
FY2022
5-year range
$611.0K / $1.4M
FY2018-FY2022
Trend
-55.6%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has declined for 4 consecutive years, from $13M in FY2018 to $611,000 in FY2022.
Based on SEC 10-K filings.
$611,000 in FY2022 with a 3-year CAGR of -59.4%.
Declined from $4M to $611,000 over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -59.4%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- CV Sciences, Inc.'s cash & equivalents has declined for 4 consecutive years.
- 3-year CAGR of -59.4%, indicating a declining trend.
- In FY2022, cash & equivalents decreased 55.6% year-over-year.
- Peak cash & equivalents was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score -8.81 (distress zone, below 1.23 threshold)
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $611.0K | -55.6% |
| FY2021 | $1.4M | -65.8% |
| FY2020 | $4.0M | -55.8% |
| FY2019 | $9.1M | -28.2% |
| FY2018 | $12.7M | - |
| FY2017 | - | - |
| FY2016 | - | - |